Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05709314 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AMDX-2011P in Participants With CAA

StatusRecruiting
PhasePhase 2
Started2024-07-09
View on ClinicalTrials.gov ↗
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).

Amendment record

Amended 6 times since 2023-01-24; most recent filed 2026-02-11. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2026-02-11
Amendment Study Identification, Study Status, Sponsor/Collaborators, Contacts/Locations v6
2024-07-29
Amendment Study Status v5
2024-04-05
Amendment Study Status, Contacts/Locations v4
2024-03-21
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
2024-02-13
Amendment Study Identification, Study Status, Sponsor/Collaborators, Study Description, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v2
2023-07-27
Amendment Study Status v1
2023-01-24
Original filing
Trial Details
NCT Number NCT05709314
Lead Sponsor Amydis Inc.
Conditions Cerebral Amyloid Angiopathy
Enrollment 25 participants
Start Date 2024-07-09
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-13